Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Olmesartan and Dapagliflozin in Healthy Volunteers
NCT04856969Phase 1Completed
- Sponsor
- Autotelic Bio
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olmesartan and dapagliflozin in hypertension (HTN) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Autotelic Bio. Primary endpoints: Area Under the Concentration-time Curve at Steady State at 10 days and Maximum Plasma Concentration at Steady State at 10 days. Started Mar 2021; status: completed.
02
Drugs
olmesartandapagliflozin
03
Conditions
hypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04856969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856969.